Christiane Jungen

Christiane Jungen

Auto-generated profile, based on publicly available information

Christiane Jungen

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KSKatharina Scherschel
Katharina Scherschel
KHKatja Hedenus
Katja Hedenus
CJChristiane Jungen
Christiane Jungen
MLMarc D Lemoine
Marc D Lemoine
NRNicole Rübsamen
Nicole Rübsamen
CMChristian Meyer
Christian Meyer
Catheter ablation for atrial fibrillation induces intracardiac neural damage characterized by glial S100B release, which promotes nerve sprouting.

30 December 2021 in EP Europace
Verified
Journal Article
Closed access
PDF file
AKAnn-Kathrin Kahle
Ann-Kathrin Kahle
CJChristiane Jungen
Christiane Jungen
FAFares-Alexander Alken
Fares-Alexander Alken
KSKatharina Scherschel
Katharina Scherschel
SWStephan Willems
Stephan Willems
CMChristian Meyer
Christian Meyer
Worldwide, ∼4 million people die from sudden cardiac death every year caused in more than half of the cases by ischaemic cardiomyopathy (ICM). Prevention of sudden cardiac death after myocardial infarction by implantation of a cardioverter-defibrillator (ICD) is the most common, even though not curative, therapy to date. Optimized ICD programming should be strived for in order to decrease the incidence of ICD interventions. Catheter ablation reduces the recurrence of ventricular tachycardias (VTs) and is an important adjunct to sole ICD-based treatment or pharmacological antiarrhythmic therapy in patients with ICM, as conclusively demonstrated by seven randomized controlled trials (RCTs) in the last two decades. However, none of the conducted trials was powered to reveal a survival benefit for ablated patients as compared to controls. Whereas thorough consideration of an early approach is necessary following two recent RCTs (PAUSE-SCD, BERLIN VT), catheter ablation is particularly recommended in patients with recurrent VT after ICD therapy. In this context, novel, pathophysiologically driven ablation strategies referring to deep morphological and functional substrate phenotyping based on high-resolution mapping and three-dimensional visualization of scars appear promising. Emerging concepts like sympathetic cardiac denervation as well as radioablation might expand the therapeutical armamentarium especially in patients with therapy-refractory VT. Randomized controlled trials are warranted and on the way to investigate how these translate into improved patient outcome. This review summarizes therapeutic strategies currently available for the prevention of VT recurrences, the optimal timing of applicability, and highlights future perspectives after a PAUSE in BERLIN.

4 August 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
PDF file
CJChristiane Jungen
Christiane Jungen
RARuken Akbulak
Ruken Akbulak
AKAnn‐Kathrin Kahle
Ann‐Kathrin Kahle
CEChristian Eickholt
Christian Eickholt
BSBenjamin Schaeffer
Benjamin Schaeffer
CMChristian Meyer
Christian Meyer
Introduction Tailored catheter ablation of atrial tachycardias (ATs) is increasingly recommended as a potentially easy treatment strategy in the era of high‐density mapping (HDM). As follow‐up data are sparse, we here report outcome after HDM‐guided ablation of ATs in patients with prior catheter ablation or cardiac surgery. Methods and Results In 250 consecutive patients (age 66.5 ± 0.7 years, 58% male) with ATs (98% prior catheter ablation, 13% prior cardiac surgery) a HDM‐guided catheter ablation was performed with the support of a 64‐electrode mini‐basket catheter. A total of 354 ATs (1.4 ± 0.1 ATs per patient; mean cycle length 304±4.3 ms; 64% macro‐, 27% localized reentry and 9% focal) with acute termination of 95% were targeted in the index procedure. A similar AT as in the index procedure recurred in 5 patients (2%) after a median follow‐up time of 535 days (interquartile range (IQR) 25th ‐ 75th percentile: 217‐841). Tailored ablation of reentry ATs with freedom from any arrhythmia was obtained in 53% after a single procedure and in 73% after 1.4±0.4 ablation procedures (range 1‐4). A total of 228 patients (91%) were free from any arrhythmia recurrence after 210 days (IQR: 152‐494) when including optimal usual care. Conclusions Tailored catheter ablation of ATs guided by HDM has a high acute success rate. The recurrence rate of the index AT is low. In patients with extensive atrial scaring further ablation procedures need to be considered to achieve freedom from any arrhythmia.

1 June 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
AKAnn-Kathrin Kahle
Ann-Kathrin Kahle
CJChristiane Jungen
Christiane Jungen
KSKatharina Scherschel
Katharina Scherschel
FAFares-Alexander Alken
Fares-Alexander Alken
CMChristian Meyer
Christian Meyer

29 November 2025 in EP Europace
Verified
Journal Article
Open access
Francesco SantoroFrancesco Santoro
Francesco Santoro
Giacomo MugnaiGiacomo Mugnai
Giacomo Mugnai
LPLaura Perrotta
Laura Perrotta
BKBoldizsar Kovacs
Boldizsar Kovacs
LDLeon Dinshaw
Leon Dinshaw
KVKevin Vernooy
Kevin Vernooy
Aims: Ventricular tachycardia (VT) in ischaemic heart disease (IHD) requires complex management strategies including catheter ablation (CA) and anti-arrhythmic drugs (AADs). The aim of this study is to compare efficacy and safety of CA vs. AADs in patients with IHD and VT. Methods and results: We performed a meta-analysis of randomized controlled trials (RCTs) enrolling patients with IHD and ICD randomized to CA or AADs. Primary outcome was appropriate ICD therapy. Secondary outcomes included inappropriate ICD therapy, cardiovascular (CV) re-hospitalization, all-cause/CV mortality, and adverse events. Subgroup analyses were conducted for amiodarone and sotalol, with an exploratory evaluation of a composite endpoint (ICD shock, VT storm, all-cause death). Four RCTs including 947 patients (mean age 68 ± 2 years; 93% male) were analysed. CA significantly reduced the risk of appropriate ICD therapy compared with AADs (149/470 [31.7%] vs. 229/477 [48.0%]; RR 0.81; 95% CI [0.67, 0.97]; P = 0.02). Among secondary outcomes, CA decreased the incidence of CV re-hospitalization [RR 0.84; 95% CI (0.72, 0.99); P = 0.04] and adverse events [RR 0.42; 95% CI (0.28, 0.62); P < 0.01], while no differences were observed in all-cause/CV mortality and inappropriate ICD therapy. In subgroup analyses, CA was superior to sotalol in reducing the composite endpoint of ICD shock, VT storm and all-cause death [RR: 0.82, 95% CI (0.69, 0.98), P = 0.03]; whereas, no significant benefit was seen compared to amiodarone [RR: 0.92; 95% CI (0.78, 1.09), P = 0.32]. Conclusion: In ischaemic heart disease and VT, CA compared with anti-arrhythmic drugs is associated with a reduction of appropriate ICD therapy, cardiovascular re-hospitalization, and adverse events with benefits most evident versus sotalol.

22 August 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
PMPaula Münkler
Paula Münkler
NKNiklas Klatt
Niklas Klatt
KSKatharina Scherschel
Katharina Scherschel
PKPawel Kuklik
Pawel Kuklik
CJChristiane Jungen
Christiane Jungen
CMChristian Meyer
Christian Meyer
Aims: Cardiac arrhythmia originating from the papillary muscle (PM) can trigger ventricular fibrillation (VF) and cause sudden cardiac death even in the absence of structural heart disease. Most premature ventricular contractions, however, are benign and hitherto difficult to distinguish from a potentially fatal arrhythmia. Altered repolarization characteristics are associated with electrical instability, but electrophysiological changes which precede degeneration into VF are still not fully understood.Methods and results: Ventricular arrhythmia (VA) was induced by aconitine injection into PMs of healthy sheep. To investigate mechanisms of degeneration of stable VA into VF in structurally healthy hearts, endocardial high-density and epicardial mapping was performed during sinus rhythm (SR) and VA. The electrical restitution curve, modelling the relation of diastolic interval and activation recovery interval (a surrogate parameter for action potential duration), is steeper in VA than in non-arrhythmia (ventricular pacing and SR). Steeper restitution curves reflect electrical instability and propensity to degenerate into VF. Importantly, we find the parameter repolarization time in relation to cycle length (RT/CL) to differentiate self-limiting from degenerating arrhythmia with high specificity and sensitivity.Conclusion: RT/CL may serve as a simple index to aid differentiation between self-limiting and electrically instable arrhythmia with the propensity to degenerate to VF. RT/CL is independent of cycle length and could easily be measured to identify electrical instability in patients.